VIVUS, Inc. (NASDAQ: VVUS) announced that additional data from the phase 3 QNEXA studies will be presented during the American Association of Diabetes Educators (AADE) meeting in Las Vegas, NV. Ronette L. Kolotkin, PhD, a clinical psychologist from Obesity and Quality of Life Consulting...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn Decision Resources' proprietary clinical gold standard in 2013 and...